{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:36:30Z","timestamp":1767108990837,"version":"3.48.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,30]]},"DOI":"10.7759\/cureus.100416","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:25:47Z","timestamp":1767108347000},"source":"Crossref","is-referenced-by-count":0,"title":["Histological Response and Prognostic Factors in Gastric Adenocarcinoma Treated With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) Chemotherapy: A Retrospective Single-Center Study"],"prefix":"10.7759","author":[{"given":"Hugo","family":"Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreia","family":"Amado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lia","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01438-6","article-title":"The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","year":"2022","unstructured":"The global burden of cancer attributable to risk factors, 2010-19. a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022, 400:563-91. 10.1016\/S0140-6736(22)01438-6","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study","volume":"5","author":"Fitzmaurice C","year":"2019","unstructured":"Fitzmaurice C, Abate D, Abbasi N, et al.. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019, 5:1749-68. 10.1001\/jamaoncol.2019.2996","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316605","article-title":"Geographic variation in molecular subtype for gastric adenocarcinoma","volume":"68","author":"Liao P","year":"2019","unstructured":"Liao P, Jia F, Teer JK, Knepper TC, Zhou HH, He YJ, McLeod HL. Geographic variation in molecular subtype for gastric adenocarcinoma. Gut. 2019, 68:1340-1. 10.1136\/gutjnl-2018-316605","journal-title":"Gut"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110173251603","article-title":"Helicobacter pylori infection and the risk of gastric carcinoma","volume":"325","author":"Parsonnet J","year":"1991","unstructured":"Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991, 325:1127-31. 10.1056\/NEJM199110173251603","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth EC","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020, 396:635-48. 10.1016\/S0140-6736(20)31288-5","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran SE","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al.. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019, 393:1948-57. 10.1016\/S0140-6736(18)32557-1","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker K","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C, et al.. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003, 98:1521-30. 10.1002\/cncr.11660","journal-title":"Cancer"},{"key":"ref9","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken MM","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5:649-55.","journal-title":"Am J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin MB","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, et al.. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging. CA Cancer J Clin. 2017, 67:93-9. 10.3322\/caac.21388","journal-title":"CA Cancer J Clin"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/14786440009463897","article-title":"On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling","volume":"50","author":"Pearson K","year":"1900","unstructured":"Pearson K. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. London Edinburgh Dublin Philos Mag J Sci. 1900, 50:157-75. 10.1080\/14786440009463897","journal-title":"London Edinburgh Dublin Philos Mag J Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177730491","article-title":"On a test of whether one of two random variables is stochastically larger than the other","volume":"18","author":"Mann HB","year":"1947","unstructured":"Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist. 1947, 18:50-60. 10.1214\/aoms\/1177730491","journal-title":"Ann Math Statist"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan EL","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53:457-81. 10.2307\/2281868","journal-title":"J Am Stat Assoc"},{"key":"ref14","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel N","year":"1966","unstructured":"Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966, 50:163-70.","journal-title":"Cancer Chemother Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34511","article-title":"Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort","volume":"153","author":"M\u00f6hring C","year":"2023","unstructured":"M\u00f6hring C, Ma\u0144czak A, Timotheou A, et al.. Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort. Int J Cancer. 2023, 153:609-22. 10.1002\/ijc.34511","journal-title":"Int J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2024.1321981","article-title":"Prognostic factors in gastric cancer patients: a 10-year mono-institutional experience","volume":"11","author":"De Ruvo N","year":"2024","unstructured":"De Ruvo N, Fenocchi S, Veronesi L, et al.. Prognostic factors in gastric cancer patients: a 10-year mono-institutional experience. Front Surg. 2024, 11:10.3389\/fsurg.2024.1321981","journal-title":"Front Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7150\/jca.49673","article-title":"Histologic lymph nodes regression after preoperative chemotherapy as prognostic factor in non-metastatic advanced gastric adenocarcinoma","volume":"12","author":"Bausys A","year":"2021","unstructured":"Bausys A, Senina V, Luksta M, et al.. Histologic lymph nodes regression after preoperative chemotherapy as prognostic factor in non-metastatic advanced gastric adenocarcinoma. J Cancer. 2021, 12:1669-77. 10.7150\/jca.49673","journal-title":"J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4780-0","article-title":"Prognostic value of differentiation status in gastric cancer","volume":"18","author":"Feng F","year":"2018","unstructured":"Feng F, Liu J, Wang F, et al.. Prognostic value of differentiation status in gastric cancer. BMC Cancer. 2018, 18:865. 10.1186\/s12885-018-4780-0","journal-title":"BMC Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.252","article-title":"Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer","volume":"115","author":"Martin-Romano P","year":"2016","unstructured":"Martin-Romano P, Sola JJ, Diaz-Gonzalez JA, et al.. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer. Br J Cancer. 2016, 115:655-63. 10.1038\/bjc.2016.252","journal-title":"Br J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5701","article-title":"Lymphovascular or perineural invasion is associated with lymph node metastasis and survival outcomes in patients with gastric cancer","volume":"12","author":"Zhang F","year":"2023","unstructured":"Zhang F, Chen H, Luo D, et al.. Lymphovascular or perineural invasion is associated with lymph node metastasis and survival outcomes in patients with gastric cancer. Cancer Med. 2023, 12:9401-8. 10.1002\/cam4.5701","journal-title":"Cancer Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01190-w","article-title":"Signaling pathways and therapeutic interventions in gastric cancer","volume":"7","author":"Lei ZN","year":"2022","unstructured":"Lei ZN, Teng QX, Tian Q, et al.. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 2022, 7:358. 10.1038\/s41392-022-01190-w","journal-title":"Signal Transduct Target Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v11.i1.48","article-title":"Unnecessity of lymph node regression evaluation for predicting gastric adenocarcinoma outcome after neoadjuvant chemotherapy","volume":"11","author":"Zhu YL","year":"2019","unstructured":"Zhu YL, Sun YK, Xue XM, Yue JY, Yang L, Xue LY. Unnecessity of lymph node regression evaluation for predicting gastric adenocarcinoma outcome after neoadjuvant chemotherapy. World J Gastrointest Oncol. 2019, 11:48-58. 10.4251\/wjgo.v11.i1.48","journal-title":"World J Gastrointest Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2022.2162090","article-title":"The impact of nutritional support on survival outcomes in patients with advanced gastric adenocarcinoma treated with chemotherapy","volume":"75","author":"Sugiyama K","year":"2023","unstructured":"Sugiyama K, Shiraishi K, Motohashi T, et al.. The impact of nutritional support on survival outcomes in patients with advanced gastric adenocarcinoma treated with chemotherapy. Nutr Cancer. 2023, 75:867-75. 10.1080\/01635581.2022.2162090","journal-title":"Nutr Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.12.021","article-title":"Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - a comparison of the FLOT and 'MAGIC' regimens","volume":"163","author":"Moore JL","year":"2022","unstructured":"Moore JL, Kumar S, Santaolalla A, et al.. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - a comparison of the FLOT and 'MAGIC' regimens. Eur J Cancer. 2022, 163:180-8. 10.1016\/j.ejca.2021.12.021","journal-title":"Eur J Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1382183","article-title":"Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer","volume":"14","author":"Zeng Z","year":"2024","unstructured":"Zeng Z, Zhu Q. Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer. Front Oncol. 2024, 14:10.3389\/fonc.2024.1382183","journal-title":"Front Oncol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19965-6","article-title":"Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer","volume":"11","author":"Sah BK","year":"2020","unstructured":"Sah BK, Zhang B, Zhang H, et al.. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nat Commun. 2020, 11:6093. 10.1038\/s41467-020-19965-6","journal-title":"Nat Commun"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143662","article-title":"Interpretation of tumor response grade following preoperative therapy for gastric cancer: an overview","volume":"15","author":"Tsagkalidis V","year":"2023","unstructured":"Tsagkalidis V, Blaszczyk MB, In H. Interpretation of tumor response grade following preoperative therapy for gastric cancer: an overview. Cancers (Basel). 2023, 15:10.3390\/cancers15143662","journal-title":"Cancers (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015321","article-title":"Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects","volume":"24","author":"Hou W","year":"2023","unstructured":"Hou W, Zhao Y, Zhu H. Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects. Int J Mol Sci. 2023, 24:10.3390\/ijms242015321","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/439947-histological-response-and-prognostic-factors-in-gastric-adenocarcinoma-treated-with-fluorouracil-leucovorin-oxaliplatin-and-docetaxel-flot-chemotherapy-a-retrospective-single-center-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:25:50Z","timestamp":1767108350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/439947-histological-response-and-prognostic-factors-in-gastric-adenocarcinoma-treated-with-fluorouracil-leucovorin-oxaliplatin-and-docetaxel-flot-chemotherapy-a-retrospective-single-center-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.100416","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}